Sugi Predict

Sugi Predict / Compounds / SCHEMBL2942200

SCHEMBL2942200

SCHEMBL2942200

CCOc1cc(CN2CC(=O)N(c3ccc(S(=O)(=O)C(F)(F)F)cc3)C2=O)ccn1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 5/20 0.47
▸ PPARD Q03181 2/20 0.41
▸ PPARA Q07869 2/20 0.41
▸ PPARG P37231 1/20 0.37
▸ ENPP2 Q13822 2/20 0.36
▸ LMNA P02545 4/20 0.35
▸ SMN1; SMN2 Q16637 4/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ FGFR1 P11362 1/20 0.33
▸ FGFR4 P22455 1/20 0.33
▸ TAS2R8 Q9NYW2 3/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ PTPRZ1 P23471 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2938148 0.91 PPARD (0.41) IGF1RPPARDPPARAPPARGENPP2
SCHEMBL2937720 0.88 ENPP2 (0.41) IGF1RPPARDPPARAPPARGENPP2
SCHEMBL2938031 0.87 IGF1R (0.45) IGF1RPPARDPPARAPPARGENPP2
SCHEMBL2938554 0.86 PPARD (0.43) IGF1RPPARDPPARAPPARGENPP2
SCHEMBL2941254 0.86 ENPP2 (0.41) IGF1RPPARDPPARAPPARGENPP2
SCHEMBL3729072 0.85 PPARD (0.42) IGF1RPPARDPPARAPPARGENPP2
SCHEMBL2937377 0.85 IGF1R (0.43) IGF1RPPARDPPARAPPARGENPP2
SCHEMBL2933162 0.85 PPARD (0.45) IGF1RPPARDPPARAPPARGENPP2
SCHEMBL2940343 0.85 IGF1R (0.49) IGF1RPPARDPPARAPPARGENPP2
SCHEMBL2936080 0.84 IGF1R (0.43) IGF1RPPARDPPARAPPARGENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 — — US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 — — EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 — — US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 — — US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 IGF1R 1595/4885PPARD 3189/4885PPARA 4338/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA IGF1R 962/4885PPARD 3572/4885PPARA 4692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.